Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE 4: once-weekly IcoSema versus daily insulin glargine in adults with type 2 diabetes inadequately controlled on oral antidiabetic drugs
jRCT2031230600Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing IcoSema with Insulin glargine (2 arms). Primary endpoint: Change in HbA1c. Started Feb 2024; status: active, not recruiting.
02
Drugs
icosemainsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031230600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230600.